Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

April 23, 2026
4 min

Fox Chase Cancer Center

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

#1

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Radiation Oncology
- Urologic Oncology
- Medical Physics
#2

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Radiation Oncology
- Urology
- Nuclear Medicine
#3

University of California, San Francisco (UCSF) Medical Center

San Francisco, CA
Key Differentiators
- Radiation Oncology
- Urology
- Medical Imaging
#4

Dana-Farber Cancer Institute / Brigham and Women's Hospital

Boston, MA
Key Differentiators
- Radiation Oncology
- Medical Oncology
- Urology
#5

Johns Hopkins Hospital

Baltimore, MD
Key Differentiators
- Radiation Oncology
- Urology
- Medical Imaging

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

Top Institutions in Radiology

MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

University of California, San Francisco (UCSF) Medical Center

Dana-Farber Cancer Institute / Brigham and Women's Hospital

Johns Hopkins Hospital

Original Source(s)

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

Related Content

Deep-Motion-Net: GNN-based volumetric liver shape reconstruction from single-view 2D projections

A spatial correlation-guided deep fusion framework for multimodal lung cancer classification using CT imaging

Multimodal data fusion: integrating PET/MRI and liquid biopsy for a holistic view of cancer biology